CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* All participants who enrolled in a CAR-T study at Froedtert Hospital \& the Medical College of Wisconsin.

Exclusion Criteria:

* There are no exclusion criteria for this study.

主要终点：Change from baseline in the incidence of a new malignancy at 5 years. · The number of subjects with new malignancy. · Baseline to five years.；Change from baseline in the incidence of a new malignancy at 10 years. · The number of subjects with new malignancy. · Baseline to 10 years.；Change from baseline in the incidence of a new malignancy at 15 years. · The number of subjects with new malignancy. · Baseline to 15 years.

• Participants who received CAR-T cells. · Participants who received CAR-T cells at Froedtert Hospital \& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)